UIM
RPRX icon

USS Investment Management’s Royalty Pharma RPRX Stock Holding History

USS Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.65M Buy
136,346
+13,987
+11% +$728K 0.03% 353
2026
Q1 		$5.87M Buy
122,359
+21,417
+21% +$938K 0.02% 340
2025
Q4 		$3.9M Buy
100,942
+24,148
+31% +$921K 0.02% 403
2025
Q3 		$2.71M Sell
76,794
-1,163
-1% -$42.1K 0.01% 465
2025
Q2 		$2.81M Sell
77,957
-41,692
-35% -$1.38M 0.02% 458
2025
Q1 		$3.72M Sell
119,649
-42,500
-26% -$1.35M 0.03% 386
2024
Q4 		$4.13M Sell
162,149
-64,457
-28% -$1.71M 0.03% 405
2024
Q3 		$6.41M Buy
226,606
+10,949
+5% +$303K 0.05% 353
2024
Q2 		$5.68M Buy
215,657
+10,008
+5% +$277K 0.05% 344
2024
Q1 		$6.25M Buy
205,649
+34,269
+20% +$1.01M 0.05% 324
2023
Q4 		$4.81M Buy
171,380
+37,778
+28% +$1.04M 0.04% 384
2023
Q3 		$3.63M Buy
133,602
+33,489
+33% +$995K 0.04% 429
2023
Q2 		$3.08M Buy
100,113
+5,374
+6% +$182K 0.04% 444
2023
Q1 		$3.41M Buy
94,739
+7,464
+9% +$277K 0.05% 419
2022
Q4 		$3.45M Buy
87,275
+3,657
+4% +$153K 0.05% 412
2022
Q3 		$3.36M Buy
83,618
+8,041
+11% +$343K 0.05% 392
2022
Q2 		$3.18M Hold
75,577
– – 0.03% 473
2022
Q1 		$2.94M Buy
75,577
+37,003
+96% +$1.45M 0.02% 530
2021
Q4 		$1.54M Hold
38,574
– – 0.01% 664
2021
Q3 		$1.39M Buy
+38,574
New +$1.5M 0.01% 676

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

USS Investment Management's RPRX Position: Q2 2026 in Review

USS Investment Management increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $728K and bringing the position to 136,346 shares worth $7.65M. The position accounts for 0.03% of the portfolio, ranked #353.

USS Investment Management first reported a position in RPRX in Q3 2021 and has held it in 20 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • USS Investment Management held 136,346 shares of Royalty Pharma worth $7.65M as of Q2 2026.
  • USS Investment Management bought 13,987 Royalty Pharma shares in Q2 2026, an estimated $728K.
  • Royalty Pharma made up 0.03% of USS Investment Management's portfolio in Q2 2026, its #353 holding.
  • USS Investment Management first reported a position in Royalty Pharma in Q3 2021 and has held it in 20 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on USS Investment Management's 13F filing for Q2 2026, filed 11 Aug 2026.